1 week Ago By Defense World Staff
Sei Investments Co. acquired a new stake in shares of C4 Therapeutics, Inc. ( NASDAQ:CCCC – Free Report ) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC.
The fund acquired 12,399 shares of the company’s stock, valued at approximately $45,000. A number of other hedge funds have also recently modified their holdings of the business. Kazazian Asset Management LLC bought a new stake in C4 Therapeutics during the fourth quarter valued at about $51,000.
China Universal Asset Management Co. Ltd. bought a new position in shares of C4 Therapeutics during the 4th quarter valued at approximately $54,000.
Y Intercept Hong Kong Ltd bought a new stake in C4 Therapeutics during the 4th quarter worth approximately $83,000. Vestcor Inc purchased a new position in C4 Therapeutics during the third quarter valued at approximately $168,000. Finally, Intech Investment Management LLC boosted its position in shares of C4 Therapeutics by 11.
1% in the fourth quarter. Intech Investment Management LLC now owns 30,150 shares of the company’s stock worth $109,000 after purchasing an additional 3,024 shares during the period. Institutional investors own 78.
81% of the company’s stock. Wall Street Analysts Forecast Growth CCCC has been the topic of a number of analyst reports. UBS Group upgraded shares of C4 Therapeutics to a “hold” rating in a research note on Friday, February 14th.
Wells Fargo & Company upgraded C4 Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $8.00 to $12.00 in a research report on Thursday, December 19th.
Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, C4 Therapeutics has an average rating of “Moderate Buy” and an average target price of $12.
50. C4 Therapeutics Price Performance NASDAQ:CCCC opened at $1.24 on Friday.
The company has a market cap of $88.03 million, a price-to-earnings ratio of -0.73 and a beta of 3.
11. C4 Therapeutics, Inc. has a 1 year low of $1.
09 and a 1 year high of $8.08. The stock’s 50 day simple moving average is $2.
30 and its two-hundred day simple moving average is $3.84. C4 Therapeutics ( NASDAQ:CCCC – Get Free Report ) last released its quarterly earnings results on Thursday, February 27th.
The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.
05). C4 Therapeutics had a negative net margin of 313.35% and a negative return on equity of 42.
45%. The business had revenue of $5.18 million for the quarter, compared to analysts’ expectations of $4.
43 million. As a group, analysts anticipate that C4 Therapeutics, Inc. will post -1.
52 EPS for the current year. C4 Therapeutics Company Profile ( Free Report ) C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.
Recommended Stories Five stocks we like better than C4 Therapeutics Differences Between Momentum Investing and Long Term Investing Robinhood Strategies Could Be a Game-Changer for Young Investors There Are Different Types of Stock To Invest In Are These 3 Retail Stocks Oversold or Really in Trouble? 3 Home Improvement Stocks that Can Upgrade Your Portfolio IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
